Wipfli Financial Advisors’s NovoCure NVCR Stock Holding History

Wipfli Financial Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$310K	Buy	+4,080	New	+$318K	0.02%	320

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wipfli Financial Advisors's NVCR Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in NovoCure (NVCR) in Q3 2022: 4,080 shares worth $310K. The stake represents 0.02% of the portfolio and ranks #320 among its holdings.

303 funds tracked by Wall St. Rank hold NVCR as of Q3 2022.

Wipfli Financial Advisors held 4,080 shares of NovoCure worth $310K as of Q3 2022.
NovoCure was a new Wipfli Financial Advisors position in Q3 2022.
NovoCure made up 0.02% of Wipfli Financial Advisors's portfolio in Q3 2022, its #320 holding.
303 funds tracked by Wall St. Rank held NovoCure as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.